Ryeqo (generic names: relugolix/estradiol hemihydrate/norethindrone) is an oral medication that can be prescribed for the treatment of moderate to severe symptoms of uterine fibroids and endometriosis-associated pain in adult women. Relugolix belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by lowering the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This reduces the production of estrogen and progesterone by the ovaries, which play a crucial role in producing conditions like uterine fibroids and endometriosis. To counter the side effects of prolonged estrogen suppression, estradiol (a form of estrogen) and norethindrone (a form of progesterone) are included in each dose of Ryeqo to maintain hormone balance and reduce the associated risks of osteoporosis. Ryeqo provides significant advantages in the management of conditions like uterine fibroids and endometriosis, which can severely impact a woman’s quality of life. Enabling the management of these conditions can reduce the need for more invasive treatments like surgery.

Dosage

The recommended dose for Ryeqo is one tablet taken with a little liquid every day, at about the same time, with or without food.